In oncology, upregulation of SEZ6L2 serves as a poor prognostic marker in several tumor entities, such as lung cancer, thyroid carcinoma, colorectal cancer, cholangiocarcinoma, hepatocellular Carcinoma, and ovarian cancer [29, 30, 31, 32, 33, 34]. Here, SEZ6L2 is linked to lung carcinoma.